ALX Oncology Reports Decreased Net Loss and Increased Assets in Latest Financial Filing

ALX Oncology Holdings Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $17.97 million, a 31% decrease from the $25.95 million loss reported in the same quarter of the previous year. For the first half of 2026, the net loss was $35.90 million, down 37% from $56.70 million in the first half of 2025. The reduction in losses is attributed to a 32% decrease in total operating expenses, which fell to $18.03 million from $26.65 million year-over-year, primarily due to lower research and development costs.

In terms of financial position, ALX Oncology's total assets increased significantly to $160.82 million as of June 30, 2026, compared to $59.05 million at the end of 2025. This growth was driven by a substantial rise in cash and short-term investments, which totaled $138.23 million, up from $44.79 million at the end of the previous fiscal year. The company’s cash and cash equivalents alone rose to $22.69 million from $16.37 million, reflecting a strong liquidity position. Additionally, stockholders' equity surged to $136.19 million, a notable increase from $25.98 million at the end of 2025, primarily due to equity offerings.

Strategically, ALX Oncology has made significant strides in its clinical pipeline, focusing on its lead product candidate, evorpacept, which is currently in multiple clinical trials. The company has also initiated a Phase 1 clinical trial for its second candidate, ALX2004, an EGFR-targeted antibody-drug conjugate. The company’s research and development expenses decreased by 27% in the second quarter of 2026, reflecting a strategic shift in clinical development that has reduced the number of active trials. This change is expected to streamline operations and focus resources on the most promising candidates.

Operationally, ALX Oncology has seen a notable increase in its employee headcount, which is now at 135, up from 54 at the end of 2025, reflecting the company's growth and expansion efforts. The company has also successfully raised capital through various equity offerings, including a recent $150 million equity offering in February 2026, which has bolstered its financial resources for ongoing and future clinical trials. The company anticipates continued investment in its research and development activities, with expectations of incurring significant expenses as it advances its product candidates through clinical trials.

Looking ahead, ALX Oncology's management has indicated that while the company has sufficient capital to fund operations through at least the first half of 2028, it will need to raise additional funds to support its ongoing clinical development and operational needs. The company plans to pursue various financing options, including equity offerings and potential collaborations, to ensure it can continue its development programs and achieve its strategic objectives in the competitive biotechnology landscape.